UT Southwestern – Cutting-edge Discoveries, Transforming Patient Care

The American Cancer Society estimates that in 2014, 63,920 people were diagnosed with kidney cancer and 13,860 people died from the disease. At UT Southwestern Harold C. Simmons Comprehensive Cancer Center, we are committed to the development of new therapies and the search for a cure.

In 2013, UT Southwestern formalized its commitment to the care of kidney cancer patients and research on kidney cancer by officially instituting a Kidney Cancer Program (KCP). The KCP includes more than 20 physicians, many of whom are renowned international leaders in their fields of urology, pediatric oncology, adult oncology, radiation oncology, radiology, and pathology. In addition, more than 40 scientists with their research laboratories are a part of the KCP.

The KCP builds on landmark discoveries made by scientists at UT Southwestern over the last three decades. Drs. Steven McKnight and David Russell discovered HIF-2α, a protein that mediates kidney cancer development. Subsequent studies by Drs. Richard Bruick and Kevin Gardnerled to the development of a drug that blocks HIF-2 activity. In addition, DJ Pan, Ph.D., discovered that the TSC1/TSC2 complex regulates TOR, which is the target of two kidney cancer drugs. Years later, James Brugarolas, M.D., Ph.D., discovered mutations in TSC1 in kidney cancer, and the presence of these mutations may identify patients most likely to respond to TOR inhibitors. Finally, recent discoveries by several investigators at UT Southwestern, including Payal Kapur, M.D., determined that there are different subtypes of kidney cancer with different biology and outcomes.

Source: http://www.utsouthwestern.edu/research/kidney-cancer/index.html

WHO WE ARE →

WHAT WE DO →

OUR STORIES →

THE KIDNEY CANCER COMMUNITY →

SCIENTIFIC ADVISORS →

DONATE →

CONTACT →

Latest News

Debra Beyhan: Embracing the Ups and Downs of Life with Kidney Cancer

Debra Beyhan: Embracing the Ups and Downs of Life with Kidney Cancer

Deb Beyhan is the Patient Legislative Advocate for KidneyCAN. She was diagnosed with stage IV kidney cancer in 2016 at the age of 53. Deb lives outside of Atlanta, GA, with her husband.    For this month's Community Spotlight, we want to tell you about a member of our volunteer team, Deb Beyhan....

DISTRICT DAYS 2022 →

SPRING ADVOCACY DAYS 2022 →

JOIN OUR COMMUNITY →

RAISING AWARENESS →

BE AN ADVOCATE →

DONATE NOW →

CONTACT →

Latest News

District Days: Asking Congress to Fund Kidney Cancer Research

District Days: Asking Congress to Fund Kidney Cancer Research

On August 8-9th, KidneyCAN gathered advocates from all over the United States to ask Congress for robust funding for kidney cancer research through the NIH and CDMRP (Congressionally Directed Medical Research Programs). Read on to hear about our goals for this event and how you can help fund...

Patient Resource Center

UNDERSTANDING YOUR KIDNEY CANCER DIAGNOSIS

BUILDING YOUR CARE TEAM

TREATMENT & TRIAL OPTIONS

LIVING WELL WITH KIDNEY CANCER

CLINICAL TRIALS →

IMMUNOTHERAPY →

KCRS: KIDNEY CANCER RESEARCH SUMMIT →

RESEARCH OPPORTUNITIES →

NEWS →

Latest News

The 2022 Kidney Cancer Research Summit

The 2022 Kidney Cancer Research Summit

Dr. Laurence Albiges (Institut Gustave Roussy) presents on the microbiome at KCRS22. The microbiome has now been recognized as one of the emerging hallmarks and enabling characteristics of cancer. KidneyCAN hosted the 4th Annual Kidney Cancer Research Summit on October 6-7, 2022  live in...

SUPPORT OUR WORK →

FUNDRAISE FOR KIDNEYCAN →

DONATE →

CONTACT →

Latest News

Rock the Run for Kidney Cancer Research Funding

Rock the Run for Kidney Cancer Research Funding

KidneyCAN had the first ever Rock the Run 5k fundraiser in October 2022. This is part of the group of KCRS22 attendees who walked and ran with us at dawn before the second conference day began. KidneyCAN is proud to share the results of the first annual Rock the Run 5K fundraiser. Our Purpose...